LunGuard

Company Overview

Snapshot

Founded in January 2009 by Ofer Pintel, LunGuard operated with 1–10 employees. The company raised $600,000 across one funding round from four investors. LunGuard ceased operations in December 2020.

Business overview

LunGuard develops a proprietary physiological integrated patient interface system designed for ICU ventilated and fed patients. Its core technology, the Reflux Prevention System (RPS), aims to reduce Ventilator Associated Pneumonia (VAP) by managing reflux and pulmonary aspiration. The system incorporates features such as intelligent reflux prevention, smart ETT cuff sealing monitoring, an integrated pulmonary pressure detector, and pH sensors for reflux indication. LunGuard's system can be integrated with any ventilator or feeding system, replacing traditional NG tubes with its own smart sensor. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving global markets.

Company Intelligence Q&A

What is LunGuard's primary focus?

LunGuard focuses on developing a reflux prevention device for ventilated and tube-fed patients, aiming to reduce complications like Ventilator Associated Pneumonia (VAP).

When was LunGuard founded?

LunGuard was founded in January 2009.

What is the status of LunGuard?

LunGuard is non-active and ceased to operate in December 2020.

What technology does LunGuard utilize?

LunGuard's technology pipeline is built around its Reflux Prevention System (RPS), which includes features like intelligent reflux prevention, smart ETT cuff sealing monitoring, and integrated pulmonary pressure detection.

What was the total capital raised by LunGuard?

LunGuard raised a total of $600K across one funding round.